Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Knowing the people you were taking advice from might have helped to make a better decision. You had plenty of guidance and good direction. Am sorry it didn't work out for you.
Good luck to you though.
"An investment I'm willing to risk".
Shorting RIMM has proven to be a better risk the past few months.
GLTU though
Game set and match. Dew Diligence declared the Match Winner. Where is the loser(s) of the match?
An apology would be appropriate after coming on this board and pumping this stock for their sole personal interests.
Just depends if you were listening to the pumper pirates who came on here.
CLSN- Celsion Reaches Major Milestone With Enrollment of 600th Patient in Its Pivotal Phase III HEAT Study of ThermoDox ( R ) in Primary Liver Cancer
COLUMBIA , MD -- ( MARKET WIRE ) -- 08 / 03 / 11 -- Celsion Corporation ( NASDAQ : CLSN ) , a leading oncology drug development company , today announced that it has reached its pre - planned enrollment objective of 600 patients in the Company ' s pivotal , Phase III HEAT study , a multinational , randomized , double - blind , placebo - controlled clinical trial of ThermoDox in combination with radio frequency ablation ( RFA ) for the treatment of primary liver cancer . The enrollment objective was established to ensure that the study ' s primary end point , progression - free survival ( PFS ) , can be achieved with adequate statistical power and is one of two triggers for an interim efficacy analysis by the study ' s independent Data Monitoring Committee ( DMC ). The second trigger is the confirmation of 190 PFS events in the study population . The HEAT study is being conducted under a U . S . Food and Drug Administration ( FDA ) Special Protocol Assessment , has received FDA Fast Track Designation , and has been designated as a Priority Trial for primary liver cancer by the National Institutes of Health .
" This milestone is a significant accomplishment for the Celsion team and our many collaborators in the global oncology community . Reaching our enrollment objective is also a critical step toward establishing ThermoDox ' s potential as a new standard of care in the first line treatment of non - resectable primary liver cancer , " said Michael H . Tardugno , President and Chief Executive Officer of Celsion . " As this potential becomes clearer in the coming months , Celsion will take steps toward ensuring a seamless commercialization process for ThermoDox and the expansion of its clinical development into other indications where it may enhance the efficacy of thermal - based oncology therapies , including recurrent chest wall breast cancer as well as metastatic liver and bone cancers . With this accomplishment , Celsion remains firmly on a path toward its evolution into a leading oncology drug development company ." " The HEAT study is the largest clinical trial ever conducted in intermediate hepatocellular carcinoma ( HCC ) and its outcome is greatly anticipated within the medical community . HCC is an aggressive , deadly disease , and one of a few cancers that is growing at an alarming rate throughout the world , " added Nicholas Borys , MD , Celsion ' s Chief Medical Officer . " We believe that adding ThermoDox to a RFA procedure will dramatically increase the hope for a cure ." The design and statistical plan of the HEAT study incorporate a pre - planned interim efficacy analysis . The HEAT study ' s independent Data Monitoring Committee will evaluate the unblinded data after the 600 patient target enrollment is reached and 190 PFS events are realized in the study population . The DMC is comprised of an independent group of medical and scientific experts with the responsibility for reviewing and evaluating patient safety and efficacy data from the HEAT study . The interim analysis is intended to evaluate safety , efficacy and futility to determine if there is overwhelming evidence of clinical benefit or a low probability of treatment success to continue , modify or terminate the study .
Consistent with the Company ' s global regulatory strategy , Celsion is continuing to enroll patients in the HEAT study in order to randomize at least 200 patients in China , a requirement for registrational filing in China . In addition to meeting the FDA enrollment objective , the HEAT study has also enrolled a sufficient number of patients to support , in Asia , registrational filings in S . Korea and Taiwan , two important markets for ThermoDox . Continued enrollment will have no effect on the timing for the pre - planned interim
for liver cancer is surgical resection of the tumor ; however , 90 % of patients are ineligible for surgery . Radio frequency ablation ( RFA ) has increasingly become the standard of care for non - resectable liver tumors , but the treatment becomes less effective for larger tumors . There are few non - surgical therapeutic treatment options available as radiation therapy and chemotherapy are largely ineffective in the treatment of primary liver cancer . About ThermoDox and the Phase III HEAT Study
ThermoDox is a proprietary heat - activated liposomal encapsulation of doxorubicin , an approved and frequently used oncology drug for the treatment of a wide range of cancers . In the HEAT study , ThermoDox is administered intravenously in combination with RFA . Localized mild hyperthermia ( 39 . 5 - 42 degrees Celsius ) created by the RFA releases the entrapped doxorubicin from the liposome . This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor . For primary liver cancer , ThermoDox is being evaluated in a 600 patient global Phase III study under an FDA Special Protocol Assessment . The study is designed to evaluate the efficacy of ThermoDox in combination with Radio Frequency Ablation ( RFA ) when compared to patients who receive RFA alone as the control . The primary endpoint for the study is progression - free survival ( PFS ) with a secondary confirmatory endpoint of overall survival . A pre - planned , unblinded interim efficacy analysis will be performed by the independent Data Monitoring Committee when enrollment in the HEAT study is complete and 190 PFS events are realized in the study population . Additional information on the Company ' s ThermoDox clinical studies may be found at www . clinicaltrials . gov .
About Celsion Corporation
Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor - targeting treatments using focused heat energy in combination with heat - activated drug delivery systems . Celsion has research , license , or commercialization agreements with leading institutions such as the National Institutes of Health , Duke University Medical Center , University of Hong Kong , the University of Pisa , and the North Shore Long Island Jewish Health System . For more information on Celsion , visit our website : http :// www . celsion . com . Celsion wishes to inform readers that forward - looking statements in this release are made pursuant to the " safe harbor " provisions of the Private Securities Litigation Reform Act of 1995 . Readers are cautioned that such forward - looking statements involve risks and uncertainties including , without limitation , unforeseen changes in the course of research and development activities and in clinical trials by others ; possible acquisitions of other technologies , assets or businesses ; possible actions by customers , suppliers , competitors , regulatory authorities ; and other risks detailed from time to time in the Company ' s periodic reports filed with the Securities and Exchange Commission .
Investor Contact
David Pitts
Argot Partners
212 - 600 - 1902
Many of us knew what was going on the entire time and did our best to share real info. As said, look at who was pumping and who was warning and learn from it. The Mod's did a good job through it all. Tough spot for them though.
... Will need cash infusion at some point
Can't say I didn't warn you. Might want to take a look back at who was pumping this stock though and driving up the price and put them on ignore so you don't walk onto the same pirate plank again.
Sorry for your losses though. There was plenty of warnings here. I even deleted a bunch of the pumping messages as much as I was allowed to anyway by the Mod's.
There are some other great buys right now out there with terrific catalysts coming up. We've been uncovering them for years now.
Isn't that what pumpers do? Generate emotion to garner others to buy, sell without saying a word and than go hide like rats. The mantra never changes. Great 4th of July weekend all. God Bless America!!
You'd think the Pirate Pumpers would come back and spare the poor souls who followed them any additional heartache. Guess true character shows at times like these. How could anyone ever take them seriously after the debacle they showed here.
Go back a few hundred posts and check out their pumping and who was doing it.
it's been rerouted to the Pirates ship and they've gone fishin. LOL
You know Pfizer is negotiating to extend their Viagra patent.
The pirate pumpers have disappeared. YooHoo Dew was right again.
Clear out Forrest and the you can easily see through the trees.
Notice the parallel? Learn anything?
------------
NovaDel Pharma Inc. (OTC BB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, announced today that Mr. Craig A. Johnson advised the Company of his resignation as Senior Vice President, Chief Financial Officer and Secretary effective July 31, 2011. The Board of Directors has agreed that Steven B. Ratoff, the Company’s President and Chief Executive Officer, will act as Interim Chief Financial Officer and Secretary until a new Chief Financial Officer and Secretary is obtained.
Mr. Johnson has served as the Company’s Senior Vice President, Chief Financial Officer and Secretary since June 2010.
“Craig has been a valuable member of NovaDel. His leadership and his efforts during his tenure with NovaDel made him a very important part of the executive team,” said Mr. Steven B. Ratoff. “I want to thank him on behalf of the Company for his many contributions to NovaDel.”
Not Sure. Stopped Following.
I'll take this reply for post 1000!
The answer is no longer a secret. Quite easy to see once the forest cleared.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=7646155
Ouch!!
Guess we know who to trust now. Convinced Yet?
Congratulations Dew Diligence on your prognostications.
This board totally ROCKS!! Guess it's the mentor moderator which helps so much!! YooHoo. Rock N Roll!!
Lovin it and Thumpin it!!!
Looks Like Dew was correct again.
What happened to all the Pirate Pumpers???? hahaha Told ya so!!
Out at .54 with 30% profits while back. Mentioned on Privateers board. Sorry for anyone who held. Bummer.
The cost per treatment is under 5 bucks. Listeria rocks! Privateers rock! io said not to buy! Kei you're smart not to go back with io. You smart girlie!! woohoo Advaxis rocks!! Go Listeria!!
wwweeeeiiiiiiiii
wwweeeeeiiiiiiii
10 bagger from when I mentioned, TWO TIMES OVER. Too bad io said not to invest here and missed out. More to coooommmmeeeeee. wwweeeiiiiiiiiiiii LISTERIA ROCKS!
Good thing I contacted U o Pa. and did my DUE DILIGENCE!!!
Awesome day all!! Rock N Roll!!
Oncothyreon prices an underwritten public offering of 10 mln shares of its common stock at a price to the public of $4.00 per share for gross proceeds of $40.0 million. 8:03 AM ET 4/29/11 | Briefing.com
Jax: Zachs didn't come through.
So what other companies do you have besides ADXS and ESPH?
up to .18 now. Last time it went into the .20's. When more analysts realize the lost cost of dose and tremendous profit per patient this should move in a nice manner.
Privateers are Rocking the Seas!
Isn't the answer pretty obvious tradergirl08?
You are welcome jklbuilder and good luck.
Whats your investing background and how did you find Advaxis?
Here's an article on the subject you mention from back in 1998. They said a few years for the wafer to be developed, erection in just a few minutes is the wafers goal. Looks like they have been working in this for quite some time.
-----------------
http://articles.nydailynews.com/1998-05-05/news/18065031_1_impotency-diamond-shaped-pills-pfizer
Pfizer Working On New, Quicker Viagra
BY CORKY SIEMASZKO
Tuesday, May 05, 1998
The good news just got better for men who take Viagra a new version of the drug that works faster is in the making.
Pfizer Inc., the makers of Viagra, said they're developing a new Viagra wafer that would enable a man to achieve an erection within minutes instead of the hour it now takes. It may take two years before the quicker Viagra is available.
But men whose love lives have been rejuvenated by Viagra said it would be hard to top what they're already taking.
"That's great that it would work faster," said Don T., a 33-year-old Brooklyn businessman who believes his impotence was caused by allergy medications and asked that his identity be withheld.
Jax:
If you want some help with I-Box put me in as Asst. Mod and will try and add in any recents.
Thanks.
This has been a nice run lately. Just sold my Calls for a 95% gain. Rock N Roll.
A great part of using the Listeria Vaccine is the cost. At just around 3 dollars a dosage the profits will be enormous here.
Have a great day!!
Great to see Advaxis getting the coverage they deserve. As a previous moderator or Asst. (can't remember) here am glad to see the board in good hands. I initially suggested buying a 100,000 shares and .025 a while back when was hanging with the kids ship. Ran to 20 cent plus range took profits and have been sitting on free shares since. Many did not take my advice but listened to io and am now suffering.
Go Advaxis, big, long and strong. Listeria Rocks!! Have spoken with Univ of Penn also. Looking very good here. Will take awhile as finding late stage cervical cancer enrollees is a challenge.
Should be a happy ending for us all.
Privateers are a rockin this sea!! Yoohoo!
Thanks for the note D. Appreciate the additional Info. Looks like things are what we thought they were. LOL!
NVDL is still down 650% from it was first rec'ed by the "DN Pirates or kids ship" as they are called. LOL
Down day today, looks like they sold, took profits and slowed the pumping.
How low will it go? Try zero. If you haven't sold yet, this would be a good time. Run Forrest Run!!
Highly recommend selling for anyone still in this DNDN Pirates highly recommended stock. They need more than a life cord. They need to phone a friend or two. Not going to happen.
Better off buying Apple Calls here.
Had been buying here with the ROBK dollars which sold off. Bought about 6k dollars in 11 and 12 cent range. Got another 30k dollars in 14 and 15 range.
This was a very easy buy with the Beach reports coming in.
Still a long way to go here yet though.
3D seismic studies yet will take a good time.
The locals, aborigininals need to fine tooth the area, all 1.2 million acres for any traces of burial grounds from their ancestors also before any drilling starts.
Should be more opportunities for you Mark to get back.
No worries.
Wouldn't buy here. Got out awhile ago. Management hasn't proved credible. Run Forest Run!!
NovaDel Announces $1.6 Million Equity FinancingA8:00 AM ET 2/15/11 | BusinessWire
NovaDel Pharma Inc. (OTCBB:NVDL) announced today that it entered into a securities purchase agreement to raise $1.6 million in gross proceeds through the sale of 1,667 shares of its Series A Convertible Preferred Stock to institutional investors having a stated value of $1,000 per share for a price of $960 per share, resulting in an original issue discount of 4%. The shares of Series A Convertible Preferred Stock are initially convertible into 16,670,000 shares of our common stock at a conversion price of $0.10 per share. The investors also received Series A Warrants, with a 5 year term, to purchase up to 16,670,000 shares of our common stock in the aggregate at an exercise price of $0.15 per share; Series B Warrants, with a 1 year term, to purchase up to 16,670,000 shares of our common stock in the aggregate at an exercise price of $0.10 per share; and Series C Warrants, with a 5 year term, to purchase up to 16,670,000 shares of our common stock in the aggregate at an exercise price of $0.15 per share. The Series B Warrants are immediately exercisable, while the Series A Warrants and Series C Warrants are only exercisable on and after February 15, 2012. The Series C Warrants may only be exercised by the holder thereof to the extent and in the same percentage that the holder exercises its Series B Warrant.
The offering closed on February 14, 2011 simultaneously with the execution of the securities purchase agreement. The net proceeds of the financing will be used primarily for the continued development of Duromist(TM), our oral spray formulation of sildenafil citrate for erectile dysfunction, development of our other product candidates and for general working capital purposes.
Roth Capital Partners served as the sole placement agent for the offering.
The shares of preferred stock, warrants and shares of common stock underlying the preferred stock and the Series B Warrant are being offered pursuant to a prospectus forming a part of the Company's effective registration statement (File No. 333-170066) filed with the Securities and Exchange Commission, a copy of which may be obtained at the SEC's website at http://www.sec.gov.
This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Additional terms of this offering (including the full terms and conditions of the securities purchase agreement, the preferred stock and warrants) are disclosed in the prospectus filed with the SEC on February 14, 2011 and on a Form 8-K filed with the SEC by NovaDel Pharma Inc. simultaneously with this press release.
NOVADEL PHARMA INC (NVDL)
File Number: 333-170066
Date of Original Registration: 10/21/10
Form Type: S-1
Securities Registered: $10,000,000 Common Stock
OUCH!!